Indication
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
7 clinical trials
12 products
6 drugs
Clinical trial
A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) a Long-acting Human IL-7, Post-Kymriah® (Tisagenlecleucel), Post-Yescarta® (Axicabtagene Ciloleucel), or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-11-01
Product
Lisocabtagene MaraleucelProduct
Axicabtagene ciloleucelProduct
TisagenlecleucelProduct
Efineptakin alfaClinical trial
IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy SyndromeStatus: Recruiting, Estimated PCD: 2024-06-01
Product
AnakinraProduct
Axicabtagene CiloleucelDrug
cyclophosphamideDrug
fludarabineClinical trial
A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-31
Product
IfosfamideClinical trial
Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell LymphomaStatus: Completed, Estimated PCD: 2024-05-28
Clinical trial
Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-05-19
Product
PembrolizumabProduct
LenalidomideDrug
TafasitamabDrug
AN0025Product
EtoposideClinical trial
A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-03-10
Product
CD47 Antagonist ALX148Drug
lenalidomideDrug
VarlilumabClinical trial
A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2027-06-15